News

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...
The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...
Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season. Skip to content Main Navigation ...
Merck’s RSV preventive antibody for infants is approved by FDA. A recommendation from the Advisory Committee on Immunization Practices must be approved by the director of the CDC or the health ...
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...
Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season. Skip to content Main Navigation ...
Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season. Skip to content Main Navigation ...
Merck's antibody-based shot met the main goal of a mid-to-late stage trial, when tested to protect infants against a disease caused by the respiratory syncytial virus (RSV), the company said on ...
Pharmalittle: We’re reading about a Merck shot for RSV, a lawsuit over an Arkansas PBM law, and more. Drugmakers met with Trump officials about lowering drug prices but no commitments were made.